PDT Partners’s VYNE Therapeutics VYNE Stock Holding History

PDT Partners’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-210	Closed	-$40K	–	835
2020 Q1	$40K	Buy	+210	New	+$65.9K	﹤0.01%	634
2019 Q3	–	Sell	-188	Closed	-$81K	–	485
2019 Q2	$81K	Buy	+188	New	+$93K	﹤0.01%	402

Other funds holding VYNE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PDT Partners's VYNE Position: Q2 2020 in Review

PDT Partners sold out of VYNE Therapeutics (VYNE) in Q2 2020, closing a stake of 210 shares — an estimated $40K sold.

PDT Partners first reported a position in VYNE in Q2 2019 and held it in 2 quarters. The position peaked at $81K in Q2 2019. 106 funds tracked by Wall St. Rank hold VYNE as of Q2 2020.

PDT Partners reported no remaining VYNE Therapeutics position as of Q2 2020 after selling out during the quarter.
PDT Partners sold 210 VYNE Therapeutics shares in Q2 2020, an estimated $40K.
PDT Partners first reported a position in VYNE Therapeutics in Q2 2019 and held it in 2 quarters.
PDT Partners's VYNE Therapeutics position peaked at $81K in Q2 2019.
106 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q2 2020.

Based on PDT Partners's 13F filing for Q2 2020, filed 14 Aug 2020.